Ventus Therapeutics Continues Phase 2a Trial of VENT-02 NLRP3 Inhibitor in Parkinson’s Disease; No Indication of Program Halt

Ventus Therapeutics is currently running a Phase 2a clinical trial of VENT-02, a brain-penetrant oral NLRP3 inhibitor, in patients with mild to moderate Parkinson’s disease1 2 4.

The first patient in this study was dosed in 2025, and the trial is designed as a randomized, double-blind, placebo-controlled study, with about 30 participants1 2 4.

The main objectives are to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and the effects of VENT-02 on biomarkers and motor function1 2 4.

There is no public information or press release from Ventus Therapeutics or major news outlets as of October 2025 indicating that the Phase 2 trial has been stopped or discontinued1 2 4 5 11.

Topline data from the Phase 2a trial are expected in late 2025 or early 20261 2 4.

VENT-02 targets NLRP3, a key driver of inflammation implicated in Parkinson's disease and other neurodegenerative or inflammatory conditions1 2 4 9.